Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Allogene Therapeutics (Nasdaq: ALLO) announced a conference call scheduled for December 13, 2021, at 1:30 PM PT/4:30 PM ET. The call will cover data from the ALPHA, ALPHA2, and UNIVERSAL Phase 1 trials concerning their AlloCAR T™ therapies for treating relapsed/refractory non-Hodgkin lymphoma and multiple myeloma. The live call can be accessed via phone or webcast, with a replay available for 30 days on their website. Allogene specializes in developing innovative, scalable cell therapies for cancer.
- Conference call to present data from Phase 1 trials, indicating ongoing clinical progress.
- Focus on developing 'off-the-shelf' CAR T cell therapies, potentially improving accessibility for patients.
- None.
- Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will host a conference call to review data to be presented at the American Society of Hematology Annual Meeting from the ALPHA and ALPHA2 Phase 1 trials in relapsed/refractory non-Hodgkin lymphoma and the UNIVERSAL Phase 1 trial in relapsed/refractory multiple myeloma on December 13, 2021 at 1:30 PM Pacific Time/4:30 PM Eastern Time.
Conference Call and Webcast Details
To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 1281484. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop AlloCAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
What is the purpose of Allogene Therapeutics' conference call on December 13, 2021?
What trials will be discussed during the Allogene Therapeutics conference call?
How can I access the Allogene Therapeutics conference call?
What are Allogene Therapeutics' AlloCAR T therapies?
What is the significance of the Phase 1 trials for Allogene Therapeutics?
